PUBLICATIONS

1. Jensen RL, Origitano TC, Lee, YS, Weber M, and Wurster RD: In-Vitro Growth Inhibition of Growth Factor-Stimulated Meningioma Cells by Calcium Channel Antagonists. Neurosurgery 36:365-374,1995.

2. Jensen RL, Lee YS, Guijarti M, Origitano TC, Wurster R, and Reichman OH: Inhibition of In-vitro Meningioma Proliferation After Growth Factor Stimulation by Calcium Channel Antagonists Part II: Additional Growth Factors, Growth Factor Receptor Immunohistochemistry, and Intra- cellular Calcium Measurements. Neurosurgery 37:937-947,1995.

3. Jensen RL,Stone JL and Hayne R: Use of the Horsley-Clarke Stereotactic Head Frame in Humans. Proceedings of the Meeting of the American Society for Stereotactic and Functional Neurosurgery, Marina del Rey, Calif.,1995,Part I Stereotact Funct Neurosurg 65: 194-197, 1995.

4. Jensen RL, Stone JL and Hayne R: Introduction of the Human Horsley- Clarke Stereotactic Head Frame. Neurosurgery 38: 563-567,1996.

5. Jensen RL, Hahn YS, Ciro E: Risk Factors of Intracranial Pressure Monitoring In Children with A Fiberoptic Device: A Critical Review. Surgical Neurology 47 :16-22, 1997.

6. Jensen RL, and Stone JL: Benjamin Winslow Dudley and Early American Trephination For Posttraumatic Epilepsy. Neurosurgery 43:263-268, 1997.

7. Jensen RL, Leppla D, Rokosz N, and Wurster RD: Matrigel augments xenograft transplantation of meningioma cells into athymic mice. Neurosurgery 42: 130-136, 1998.

8. Jensen RL: Growth Factor Mediated Angiogenesis in the Malignant Progression of Glial Tumors. A Review. Surgical Neurology 49: 189-96, 1998.

9. Kristopulos T, Jensen RL, Lee J, and Guijarti M: Clostridium perfringens: as a rare cause of postoperative spinal surgery meningitis. Surgical Neurology 51: 448-51, 1999.

10. Jellish WS, Jensen RL, Anderson DE and Shea JF: Intraoperative electromyographic assessment of recurrent laryngeal nerve stress and pharyngeal injury during anterior cervical spine surgery with Caspar instrumentation. J Neurosurgery (Spine 2) 91 : 170-174, 1999.

11. Jensen RL., M Petr, and Wurster RD. Calcium channel antagonist effect on in vitro meningioma signal transduction pathways after growth factor stimulation. Neurosurgery 46 : 692-703, 2000.

12. Galloway EB, Jensen RL, Dailey AT, Thompson BG, and Shelton C. Role of Topical Steroids in Reducing Dysfunction After Nerve Injury. Laryngoscope 110: 1907-1910, 2000.

13. Jensen RL, and Wurster RD. Calcium channel antagonists inhibit growth of subcutaneous xenograft meningiomas in nude mice. Surgical Neurology. 55: 275-283, 2001.

14. Shrieve DC, Watson GA, Jensen RL, and Leavitt DL: Conformity of LINAC-based stereotactic radiosurgery using dynamic conformal arcs and mini-multileaf collimator. Int J Radiation Oncology Biol Phys.51: 126 Suppl 1, 2001.

15. Jensen RLL, Soleau S, Bhayani MK, and Christiansen D: Expression of hypoxia inducible factor 1± and correlation with preoperative embolization of meningiomas. J Neurosurgery 97: 658-667, 2002.

16. Rao G and Jensen RL: Coexistant cerebral metastasis and cavernous. J Neurol Neurosurg Psychiatry 74: 105, 2003.

17. Ragel B and Jensen RL: New approaches for the treatment of refractory meningiomas. Cancer Control 10: 148-158, 2003.

18. Kan Peter and Jensen RL: Primary malignant cerebropontine angle melanoma presenting as a presumed meningioma: Case report and review of the literature. Skull Base Surgery 13: 159-166, 2003.

19. Liu JK, Schmidt M, MacDonald JD, Jensen RL, and Couldwell WT: Hypophyseal transposition (hypophysopexy) for radiosurgery of pituitary turmos involving the cavernous sinus. Technical note. Neurosurg Focus 14: Article 11, 2003.

20. Liu JK, O'Neill B, Orlandi RR, Moscatello AL, Jensen RL, and Couldwell WT: Endoscopic-assisted craniofacial resection of esthesioneuroblastoma: Minimizing facial incisions. Technical note and report of 3 cases. Minimally Invasive Neurosurgery 46: 310-315, 2003.

21. Gilbert E, Shelton C, Harnsberger R, Jensen RL: Meningioma of the jugular foramen: Glomus jugulare mimic and surgical challenge. Laryngoscope 114: 25-32, 2004 .

22. Kan P, Gottfried, O, Blumenthal D, Townsend J, and Jensen R. Oligodendroglioma and Juvenile Pilocytic Astrocytoma Presenting as Synchronous Primary Brain Tumors: Case Report and Review of the Literature. J Neurosurgery 100: 700-705, 2004.

23. Jensen RL, Gillespie D, House P, Layfield L, and Shelton C: Endolymphatic Sac Tumors In Patients With And Without Von Hippel Lindau Disease: The Role of VHL Genetic Mutation, VHL Protein and Hypoxia Inducible Factor-1± (HIF-1±) Expression. J Neurosurgery 100: 488-497, 2004.

24. House P, Salzman K, Osborn A, MacDonald J, JJensen RL, and Couldwell. W: Surgical Considerations Regarding Giant Dilations of the Perivascular Spaces. J Neurosurgery 100:820-824, 2004.

25. Ragel B and Jensen RL: Pathophysiology of Meningiomas. Seminars in Neurosurgery 14: 169-185, 2004.

26. Jensen RL: Cauda equina syndrome as a post-operative complication of non-instrumentated lumbar spine surgery. Neurosurgical Focus, June 15, 2004.

27. Shrieve DC, Hazard L, Boucher K, and Jensen RL: Dose fractionation in stereotactic radiotherapy for parasellar meningiomas: Radiobiological j considerations of efficacy and optic nerve tolerance. J Neurosurg (Suppl l 3) 101: 390-395, 2004.

28. Patel SJ, Shapiro WR, Laske DW, Jensen RL, Asher T, Wessels BW: Safety and Feasibility of Convection-Enhanced Delivery (CED) of Cotara for the treatment of malignant glioma: Initial experience in 51 patients. Neurosurgery 56:1243-1253, 2005

29. Rogers L, Jensen RL, and Perry A: Chasing your dural tail. Editorial accepted for publication in the Int J Rad Oncol Biol Phys, 2005.

30. Ragel B, Jensen RL, Gillespie D, Prescott S, and Couldwell W: d Cyclooxygenase-2 (COX-2) Is Ubiquitously Expressed in Meningiomas s and Treatment in Vitro and COX-2 Inhibitor Celecoxib Decrease Cell d Growth: Potential Therapeutic Application. Accepted for Publication in J Neurosurgery, September 2005.

31. Rao G, Klimo P, Jensen RL, MacDonald JD, and Couldwell WT: Recurrent craniofacial meningiomas. Accepted to J Neurosurgery

32. Layfield LJ, Wilmore C, Tripp S, Jones C, and Jensen RL: Epidermal growth factor receptor (EGFR) gene amplification and protein expression in glioblastoma multiforme: Prognostic significance and relationship to other prognostic factors: Submitted to Am J Pathology

33. Jensen RL, Ragel B, Whang K, and Gillepsie D: Hypoxia inducible factor 1± Is the Major Regulator of Vascular Endothelial Growth Factor (VEGF) Secretion in Human Gliomas. Submitted to Neurosurgery.

34. Rao G, Klimo P, Thompson CJ, Samlowski W, Chang M, Watson G, Shrieve D, and Jensen RL: Stereotactic radiosurgery as therapy for melanomas, renal carcinoma, and sarcoma brain metastases: Impact of added surgical resection and whole brain radiotherapy. Submitted to Int J Rad Onc Phys Biol.

35. Chern SS, Leavitt DD, Jensen RL, and Shrieve DC: Is smaller better? Comparison of 3 mm and 5 mm leaf size for stereotactic radiosurgery: A dosimetry study. Submitted to Int J Rad Oncol Physic Biol.

36. Kan P, Gottfried O, Liu JK, Blumenthal D, Townsend J, and Jensen RL. Primary Yolk Sac Tumor of the Conus Medullaris: Case Report and Review of the Literature. Submitted to J Neurooncology.

37. Jensen RL, Camano E, Couldwell WT: Mesial temporal lobe lesion with new onset of gadolinium enhancement after 15 years of observation but at surgery found to be a ganglioglioma. Submitted to J Neuro Oncology

38. McCall T, Binning M, Blumenthal D, Jensen RL: Variation of choroids plexus papilloma dissemination. Submitted to Neurosurgery.

39. Finn MA, Blumenthal DT, Salzman KL, Jensen RL: Transient post-ictal MRI changes in patients with brain tumors may mimic disease progression. Submitted to J Neurosurgery.

40. McCall T, Rao G, and Jensen RL: Development and rapid growth of a desmoid tumor in the surgical corridor following suboccipital craniotomy for recurrent low grade astrocytoma. Submitted to J Neurosurgery.

41. Rogers LR, Sills AK, Vogelbaum MA, Suh JH, Rock JP, Ellis TI, Stieber VW, Asher AL, Fraser RW, Billingsley JS, Arrambide S, Jensen RL, and Shaw E: Initial results of phase II study utilizing the Gliasite RTS for the treatment of a resected single brain metastasis. Submitted to Neurosurgery.

42. Ragel BT, Blumenthal DT, Browd SR, and Jensen RL: Intracerebral Amyloidoma Can Mimic High Grade Glioma on Magnetic Resonance Imaging and Spectroscopy (MRI/MRS). Submitted to Neurooncology.

43. Ragel BT, Couldwell WR, McCutcheon I, Wendlend M, Whang K, Gillespie DL, and Jensen RL. A comparison of cell lines involved in meningioma research. In preparation.

44. Jensen RL, Gillespie D, Ragel B, and Wurster RD: Treatment of Human Meningiomas with Calcium Channel Antagonists Potentiates Chemotherapeutic Response. In preparation.

45. Gupta DK, Baker DL, Robinson JC, Jensen RL, and Egain TD: Cerebral venous sinus thrombosis as a cause of delayed awakening and severe cerebral edema during an awake craniotomy for speech mapping. Submitted to Neuroanesthesia

46. Ragel B, Whang K, Osborn AG, Townsend JJ, Jensen RL, House P, and Couldwell: Clinical and radiographic analysis of eight subependymomas. case series and review of the literature. Submitted J Neurosurgery.

47. Gillepsie D and Jensen RL: Short inhibitory RNA inhibition of hypoxia a inducible factor-1 decreases glioma growth in vivo and invitro. In a preparation.

48. Jensen RL, O'Rouke D, Sampson J, Warnick R, Sawaya R: Resident a training in Neuro Onocology. Survey results of North American Training Programs. In Preparation, will submit to J of Neuro Oncology.


PRESENTATIONS

1. Jensen RL, Davis RK, Straight RC. The Eradication of Invasive Tumors with Intraoperative Photodynamic Therapy. Presented at the Western Section of the Federation of Research, Carmel, California, February, 1989.



2. Jensen RL, Davis RK, Straight RC. Intraoperative Photodynamic Therapy for the Eradication of Aggressive and Invasive Tumors. Presented at The American Academy of Otolaryngology-Head and Neck Surgery Research Forum in New Orleans on September 25, 1989.

3. Jensen RL, Davis RK, and Straight RC. Photodynamic Therapy with Photofrin II and Acridine Orange Combined. Presented at the American Society for Lasers in Medicine and Surgery National Meeting in Nashville, Tennessee. April 6,7 and 8, 1990.

4. Jensen RL, Davis RK, Straight RC. Combination Phototherapy With Photofrin II and Acridine Orange. Presented at The American Academy of Otolaryngology-Head and Neck Surgery Research Forum in San Diego, California on September 9-13, 1990.

5. Jensen RL, Davis RK, Straight RC. A Comparison of the Localization and Retention Profiles of Methylene Blue, Acridine Orange, and Photofrin II. Presented at the American Society for Lasers in Medicine and Surgery National Meeting in San Diego, California. April 29,30 and May 1, 1991.

6. Jensen RL, Davis RK, Straight RC. A New Approach to Photodynamic Therapy with Methylene Blue. Presented at the American Society for Lasers in Medicine and Surgery National Meeting in San Diego, California. April 29,30 and May 1, 1991.

7. Jensen RL, Origitano TC, Wurster R, Lee YS: In Vitro Growth Inhibition of De Novo Meningioma Cells with Calcium Channel Antagonists. Presented at the North American Skull Base Society Scientific Session, Orlando, Florida, February, 1994.

8. Jensen RL, Origitano TC, Wurster R, Lee YS: The use of calcium channel blocking agents for inhibition of meningioma cell growth in vitro: Laboratory studies and clinical implications. Presented at Neurosurgery in Jackson Hole, Jackson Hole, Wyoming, March, 1994.

9. Jensen RL, Hahn YS, Ciro E: Fiberoptic Intracranial Pressure Monitoring: Experience with 98 Consecutive Patients. Presented at the American Association of Neurological Surgeons Annual Meeting, San Diego, April, 1994.

10. Jensen RL, Origitano TC, Lee YS, Wurster RD and Reichman OH., Growth Factor-Stimulated Proliferation of in-vitro Meningiomas can be Inhibited by Calcium Channel Antagonists. Presented at the Second Annual Growth Control in Central Nervous System Tumors Symposium, Boston, MA, May 20-21,1994.

11. Hahn YS, Jensen RL, Ciro E: Risk Factors of Intracranial Pressure Monitoring In Children with A Fiberoptic Device: A Critical Review. Presented at The International Society for Pediatric Neurosurgeons Annual Meeting, Birmingham, UK, September, 1994.

12. Hahn YS, Jensen RL, Ciro E: Risk Factors of Intracranial Pressure Monitoring In Children with A Fiberoptic Device: A Critical Review. Presented at The Congress of European Society for Pediatric Neurosurgery, Lyon, France, September, 21-23, 1994.

13. Jensen RL, Origitano TC, Wurster R, Lee YS: In Vitro Growth Inhibition of Growth Factor-Stimulated Meningioma Cells by Calcium Channel Antagonists. Presented at The Congress of Neurological Surgeons Annual Meeting, Scientific Session, Chicago, Illinois, October, 1994.

14. Jensen RL, Origitano TC, Lee YS, Wurster RD and Reichman OH: The Proliferation of Growth Factor-Stimulated Primary Meningioma Cell Cultures can be Inhibited by Calcium Channel Antagonists. Presented at the The Congress of Neurological Surgeons Annual Meeting, Tumor satellite symposium, Chicago, Illinois, October 6-7, 1994.

15. Jensen RL, Origitano TC, Lee YS, Wurster RD and Reichman OH: Growth Factor-Stimulated Proliferation of In-vitro Meningiomas can be Inhibited by Calcium Channel Antagonists. Presented at Annual Meeting of Society for Neuroscience, Miami Beach, Florida, November 13-18,1994.

16. Jensen RL, Origitano TC, Wurster R, Lee YS: Growth Inhibition of De Novo Meningioma Cells with Calcium Channel Antagonists. Presented at the Richard Lende Winter Neurosurgical Conference, Snowbird, Utah, February 3-8, 1995.

17. Jensen RL, Origitano TC, Wurster R, Lee YS: In Vitro Growth Inhibition of De Novo Meningioma Cells with Calcium Channel Antagonists. Presented at the North American Skull Base Society Sixth Annual Meeting, Scientific Session, Naples, Florida, February 18-25, 1995.

18. Jensen RL, Stone JL, and Hayne RA: Introduction of the Human Horsley- Clarke Stereotactic Frame. Presented at the Quadrennial Meeting of The American Society For Stereotactic and Functional Neurosurgery, Marina del Rey, California, March 8-11,1995.

20. Jensen RL, Lee YS, Guijarti M, Origitano TC, Wurster RD and Reichman OH: Inhibition of In-vitro Meningioma Proliferation After Growth Factor Stimulation by Calcium Channel Antagonists Part II: Additional growth factors, growth factor receptors immunohistochemistry, and intracellular calcium measurements. Presented at the American Association of Neuro- logical Surgeons Annual Meeting, Orlando, Florida, April, 22-27, 1995.

21. Jensen RL, Anderson DE, Thalji Z, and Jellish S: Intraoperative recurrent laryngeal nerve monitoring during anterior cervical discectomy. Presented at the American Association of Neurological Surgeons Annual Meeting, Minneapolis, Minnesota, April, 22-27, 1996.

22. Wurster RD and Jensen RL: Calcium channel antagonists as anticancer agents. Presented at the Meeting of Anticancer Targets and Strategies for the Twenty-First Century. Castres, France, October 9-11, 1996

23. Jensen RL and Stone JL: Stereotactic cerebral localization: Origin, evolution and future. Presented at the Annual Meeting of Society for Neuroscience, Washington, D.C. November 12-17,1996.

24. Jensen RL, Origitano TC, Wurster R, Reichman O.H: Calcium channel antagonist growth inhibition of meningioma cell growth: eludication of mechanism and in vivo experiments. Presented at the Richard Lende Winter Neurosurgical Conference, Snowbird, Utah, February 1-8, 1997.

25. Jensen RL, Gruener G, and Origitano TC: Post-ventriculoperitoneal shunt infection Parkinsonism. Case report, video exam, literature review. Presented at the Richard Lende Winter Neurosurgical Conference, Snowbird, Utah, February 1-8, 1997.

26. Jensen RL, Leppla D, Rokosz N, Wurster R: Matrigel augments tumor take and tumor mass in xenograft transplantation of cultured meningioma cells into athymic mice. Presented at the North American Skull Base Society Eighth Annual Meeting, Scientific Session, Little Rock, Arkansas, March 22-25, 1997.

27. Jensen RL, T. C. Origitano, Wurster R: Status of current basic research of meningioma development and proliferation. A review. Presented at the North American Skull Base Society Eighth Annual Meeting, Scientific Session, Little Rock, Arkansas, March 22-25, 1997.

28. Jensen RL, Kristopulos C, Guijartic M, and Anderson DE: Clostridium perfringes as a rare cause of postoperative spinal surgery meningitis. Presented at the American Association of Neurological Surgeons Annual Meeting, Denver, Colorado, April, 12-17, 1997.

29. Jensen RL: Meningioma Growth Inhibition by calcium channel antagonists. Neurology/Neurosurgery Grand Rounds. University of Utah School of Medicine. July 23, 1997.

30. Jensen RL, Leppla D, Rokosz N, Wurster R: Subcutaneous xenograft transplanatation of meningioma cells into athymic mice using a Matrigel matrix. Presented at the Congress of Neurological Surgeons Annual Meeting, Scientific Session, New Orleans, Louisiana, Sept. 27-Oct. 2, 1997.

31. Jensen RL, Anderson DE, Thalji Z, and Jellish S: Recurrent laryngeal nerve monitoring during anterior cervical spinal procedures using intraoperative posterior pharyngeal electromyography. Presented at the Congress of Neurological Surgeons Annual Meeting, Scientific Session, New Orleans, Louisiana, September 27-October 2, 1997.

32. Jellish WS, Thalji A, Jensen RL, Anderson DE: Intraoperative compound electromyography of posterior pharynx as a method to detect recurrent layrngeal nerve injury during anterior cervical spine procedures. Presented at the 1997 Annual Meeting of the Society of Anesthesiologists, San Diego, CA. October 18-22. 1997.

33. Jellish WS, Thalji A, Jensen RL, Anderson DE: Electromyography used during anterior cervical spine procedures to detect recurrent layrngeal nerve injury. Presented at the 25th Annual Meeting of the Society of Neurosurgical Anesthesia and Critical Care. San Diego, CA. October 17. 1997.

34. Jensen RL, and Wurster RD: Investigations of mechanisms of calcium channel antagonist growth inhibition of meningioma cell growth in vivo. Presented at the 27th Annual Meeting of Society for Neuroscience, New Orleans, October 25-30,1997.

35. Jensen RL, and Stone JL: Benjamin Winslow Dudley and early American trephination for posttraumatic epilepsy. Presented at the 27th Annual Meeting of Society for Neuroscience, New Orleans, October 25-30,1997.

36. Jensen RL and Jellish S: Intraoperative posterior pharyngeal electromyography for the prevention of recurrent laryngeal nerve injury during anterior cervical spine procedures. Presented at the Richard Lende Winter Neurosurgical Conference, Snowbird, Utah, February 1-8, 1998.

37. Jensen RL, Leppla D, Rokosz N, Wurster R: Matrigel augments the subcutaneous xenograft transplantation of meningioma cells into athymic mice. Presented at the American Association of Neurological Surgeons Annual Meeting, Scientific Session, Philadelphia, Pennsylvania, April 25- 30, 1998.

38. Jensen RL, Anderson DE, Thalji Z, and Jellish S: Intraoperative recurrent laryngeal nerve monitoring during anterior cervical spine procedures with posterior pharyngeal electromyography. Presented at the American Association of Neurological Surgeons Annual Meeting, Scientific Session, Philadelphia, Pennsylvania, April 25-30, 1998.

39. Jensen RL, Gruener G, and Origitano TC: Post-ventriculoperitoneal shunt infection Parkinsonism. Presented at the American Association of Neurological Surgeons Annual Meeting, Scientific Session, Philadelphia, Pennsylvania, April 25-30, 1998.

40. Jensen RL, Leppla D, Rokosz N, Wurster R: Matrigel augments the subcutaneous xenograft transplantation of meningioma cells into athymic mice. Presented at AANS/CNS Tumor Satellite Symposium, Philadelphia, Pennsylvania, April 30 - May 1, 1998.

41. Jensen RL Growth factor medicated angiogenesis in the malignant progression of glial tumors. A review. Presented at AANS/CNS Tumor Satellite Symposium, Philadelphia, Pennsylvania, April 30 - May 1, 1998.

42. Jensen RL Meningioma turmorigenesis and proliferation. A review. Presented at AANS/CNS Tumor Satellite Symposium, Philadelphia, Pennsylvania, April 30 - May 1, 1998.

43. Jensen RL, Petr M, Wurster RD. Calcium channel antagonist effection of in vitro meningioma intracellular calcium and inositol phosphate metabolism.Presented at the Congress of Neurological Surgeons Post Satellite Meeting-Semi-Ah-Moo Resort, Blaine, Washington. October 10, 1998.

44. Jensen RL: Vascular Endothelial Growth Factor: Common denominator of intracranial tumor vascularity, peritumoral edema, and thromboembolic complications. University of Utah Neurology/Neurosurgery Grand Rounds, October 14, 1998.

45. Jensen RL, Petr M, and Wurster RD: Calcium Channel Antagonist alterations of intracellular calcium and inositol phosphate signaling in human cultured meningiomas. Presented at the 28th Annual Meeting of Society for Neuroscience, Los Angeles, November 7-12,1998.

46. Jensen RL: Vascular Endothelial Growth Factor-mediated glioma angiogenesis requires simultanteous, multiple growth factor stimulation. Presented at the Richard Lende Winter Neurosurgical Conference, Snowbird, Utah, January 30 - February 5, 1999.

47. Jensen RL, Petr M, and Wurster RD: In vitro meningioma cell intracellular calcium and inositol phosphate are disrupted by calcium antagonists. Presented at the American Association of Neurological Surgeons Annual Meeting, Scientific Session, New Orleans, Louisana, April 24-29, 1999.

48. Jensen RL: Calcium channel antagonist effect on in vitro meningioma signal transduction pathways after growth factor stimulation. North American Skull Base Society 1999 Annual Meeting. Chicago, Illinois, May 28-31, 1999.

49. Jensen RL: Long-Term Results with Foramen Magnum and Craniocervical Junction Tumors. Panel discussant, Speaker. North American Skull Base Society 1999 Annual Meeting. Chicago, Illinois, May 28-31, 1999.

50. Jensen RL: Preoperative Functional Work-up and Intraoperative Mapping of Intrinsic Brain Tumors, and the Biology of Meningiomas. Visiting Professor, Loyola University of Chicago October 12 -13, 1999

51. Jensen RL : Biology of Meningiomas. Invited speaker, Plenary Session. Joint Section on Tumors. Congress of Neurological Surgeons Annual Meeting, Boston, Massachusetts, October 30 - November 3, 1999.

52. Jensen RL, Wurster RD: Calcium channel antagonist effect on in vitro meningioma signal transduction pathways after growth factor stimulation. Congress of Neurological Surgeons Annual Meeting, Boston, Massachusetts, October 30 - November 3, 1999.

53. Jensen RLL. Brain Protection. Anesthesiology Grand Rounds. University of Utah School of Medicine, January 20, 2000.

54. Jensen RL: Vascular endothelial growth factor secretion is mediated by growth factor stimulation and hypoxia. Richard Lende Winter Neurosurgical Conference, Snowbird, Utah, January 29 - February 3, 2000.

55. Jensen RL, and Wurster RD. Vascular endothelial growth factor (VEGF) secretion in meningiomas is regulated by hypoxia and growth factors. 11th Annual Meeting of the North American Skull Base Society. Scottsdale, Arizona, March 17-20, 2000.

56. Galloway EB, Jensen RLL, Dailey AT, Thompson BG, and Shelton C. Topical Steroids: Do they reduce dysfunction following nerve injury? Presented at the Western Section of the Triologic Society Meeting, San Francisco, March, 2000.

57. Jensen RL, and Wurster RD. Calcium Channel Antagonists Inhibit the Growth of Subcutaneous Xenograft Meningiomas in Nude Mice. American Association of Neurological Surgeons, San Francisco, April 9-13, 2000.

58. Jensen RL: Mechanisms of Hypoxia-induced and Growth Factor Stimulated Vascular Endothelial Growth Factor Secretion in Intracranial Tumors. Fourth Biennial AANS/CNS Section on Tumor Satellite Symposium, San Francisco, California, April 13-14, 2000.

59. Jensen RL: Management of Cerebral Metastatic Disease 2000. University of Utah Neurology/Neurosurgery Grand Rounds, April 19, 2000.

60. Jensen RL: Hypoxia Induced Vascular Endothelial Growth Factor Secretion in Intracranial Tumors. 2000 Rocky Mountain Neurosurgical Society. Alyeska, Alaska, June 24-28, 2000.

61. Jensen RL and Wurster RD. Calcium channel antagonist effect on xenograft meningiomas: Growth Studies, histological analysis, and proliferative indices. Congress of Neurological Surgeons Annual Meeting, San Antonio, Texas, September 23-28, 2000.

62. Jensen RL: Diseases of the Cavernous Sinus: Work-up, Management, and Surgical Anatomy. University of Utah Neurology Neurosurgery Grand Rounds. September 20, 2000.

63. Jensen RL: Vascular Endothelial Growth Factor Expression is Controlled by Hypoxia and Growth Factor Stimulatio in Intracranial Tumors. Fifth Annual Meeting Society of Neuro-Oncology, Chicago, Illinois, November 9-12, 2000.

64. Jensen RL: Postoperative cauda equina syndrome after lumbar spine procedures. Richard Lende Winter Neurosurgical Conference, Snowbird, Utah, January - February 2-8, 2001.

65. Jensen RL: The role of hypoxia inducible factor in vascular endothelial growth factor secretion after growth factor stimulation and hypoxia. American Association of Neurological Surgeons, Toronto, Ontario, Canada, April 21-24, 2001.

66. Patel SJ, Laske D, Jensen RL, Asher A, and Chew T: Phase 2 results of an open label study of interstitial 131I-ch-TNT-1/B for the treatment of newly diagnosed or recurrent malignant glioma. American Society of Clinical Oncology, May 2001.

67. Shrieve DC, Watson GA, Jensen RL, Heilbrun MP, and Leavitt DL: Conformality of LINAC-based SRS utilizing dynamic arcs with MMLC. ASTRO, 2001.

68. Jensen RLL: Hypoxia inducible factor-1± mediated VEGF expression after hypoxic and growth factor stimulation in glioblastoma multiforme. International Brain Tumor Meeting. Asheville, North Carolina, May 26-31, 2001.

69. Rao G and Jensen RL: Co-existing cavernous angioma and metastatic brain tumor. Imaging studies, pathology and management. Rocky Mountain Neurosurgery Society, Steamboat Springs, June 16-21, 2001.

70. House P and Jensen RL: Temporal lobe subependymoma. Case description and imaging studies. Rocky Mountain Neurosurgery Society, Steamboat Springs, June 16-21, 2001.

71. Jensen RL: Tissue diagnosis in neurooncology; necessity or antiquated by modern imaging techniques. Rocky Mountain Neurosurgery Society, Steamboat Springs, June 16-21, 2001.

72. Jensen RL and Frantz D. Hypoxia inducible factor 1± mediated vascular endothelial growth factor secretion in intracranial tumors. Congress of Neurological Surgeons. San Diego, California. September 29-October 4, 2001.

73. Jensen RL: Hypoxia inducible factor 1± in intracranial tumors. University of Utah Neurology/Neurosurgery Grand Rounds, August 18, 2001.

74. Jensen RL, and Frantz D: The role of hypoxia inducible factor-1 in vascular endothelial growth factor expression in glioblastoma multiforme under normoxic and hypoxic conditions. Sixth Annual Meeting Society of Neuro-Oncology, Washington, DC, November 15-18, 2001.

75. Wessels P, Jensen RL, Patel S, Nelson AB, Bouchet CD, Shan J, and Chew T: Image fusion and patient specific dosimetry for tumor response and toxicity evaluation in patients with gliomas undergoing radionucliotide therapy. Sixth Annual Meeting Society of Neuro- Oncology, Washington, DC, November 15-18, 2001.

77. Kan Peter and Jensen RL: Indolent Jugular Foramen Primary Central Nervous System Melanoma Though To Be A Meningioma. Richard Lende Winter Neurosurgical Conference, Snowbird, Utah, February 3-8, 2002.

78. Jensen RL, Soleau S, Bhayani MK, and Christiansen D: Hypoxia Inducible Factor-1± (HIF-1±) Regulation of Vascular Endothelial Growth Factor (VEGF) Secretion in Meningiomas: Effect of In vivo Preoperative Embolization and In vitro Hypoxia on Primary Meningioma Cell Cultures. Richard Lende Winter Neurosurgical Conference, Snowbird, Utah, February 3-8, 2002.

79. Jensen RLL, Treatment of Human Meningiomas with Calcium Channel Antagonists. American Association of Neurological Surgeons Annual meeting, Chicago, Illinois, April 5-10, 2002.

80. Panner AS, Zainelli GM, Jensen RL, Origitano TC, and Wurster RD: Possible correlation between T-type calcium channel expression and degree of proliferation of intracranial tumor cells. American Association of Neurological Surgeons Annual meeting, Chicago, Illinois, April 5-10, 2002.

81. Jensen RL Hypoxia Inducible Factor-1 Control of Intracranial Tumor Growth and Angiogenesis Presented at AANS/CNS Tumor Satellite Symposium, Chicago, Illinois, April 11 - 12, 2002.

82. Jensen RL: Primary Central Nervous System Lymphoma: Uncommon But Confounding Factor In Neuro-oncology. Rocky Mountain Neurosurgery Society Annual Meeting, Sante Fe, New Mexico, June 14th-18th, 2002.

83. House P and Jensen RL: Endolymphatic Sac Tumors as part of the von Hippel-Lindau syndrome: Molecular biology and relation to Hypoxia Inducible Factor-1 regulation. Rocky Mountain Neurosurgery Society Annual Meeting, Sante Fe, New Mexico, June 14th-18th, 2002.

84. Jensen RL, and Gillepsie D: Modificaton of Hypoxia Inducible Factor-1 expression in Glioblastoma Multiforme Alters Growth and Angiogenesis Seventh Annual Meeting Society of Neuro-Oncology, San Diego, CA, November 21-24, 2002.

85. Watson GA, Romney D, Samlowski WE, Jensen RL, and Shrieve DC: LINAC based stereotactic radiosurgery for renal cell and melanoma brain metastases: prognostic factors for overall survival and local control. Seventh Annual Meeting Society of Neuro-Oncology, San Diego, CA, November 21-24, 2002.

86. Jensen RL, Shrieve D, Fults D, and Watson G: Gliasite Radiation Therapy System for Treatment of Recurrent Malignant Gliomas and Metastatic Brain Tumors. University of Utah Experience. Richard Lende Winter Neurosurgical Conference, Snowbird, Utah, February 1-7, 2003.

87. Jensen RL, and Gillespie D: Hypoxia Inducible Factor-1 Expression in Glioblastoma Multiforme Controls Vascular Endothelial Growth Factor Secretion, Angiogenesis, and Tumor Growth. Richard Lende Winter Neurosurgical Conference, Snowbird, Utah, February 1-7, 2003.

88. Klimo P, Blumenthal D, and Jensen RL: Richter's syndrome-A rare form of primary CNS lymphoma. Richard Lende Winter Neurosurgical Conference, Snowbird, Utah, February 1-7, 2003.

89. Rao G, Watson G, Shrieve D, and Jensen RL: Experience at the University of Utah with LINAC based stereotactic radiosurgery for patients with “radioresistant” cerebral metastases. Richard Lende Winter Neurosurgical Conference, Snowbird, Utah, February 1-7, 2003.

90. Ragel B and Jensen RL: New approaches for the treatment of refractory meningiomas. Richard Lende Winter Neurosurgical Conference, Snowbird, Utah, February 1-7, 2003.

91. Jensen RL. Cortical Mapping. Breakfast Seminar. American Association of Neurological Surgeons Annual meeting, San Diego, CA, April 26-May 1, 2003.

92. Jensen RL. Discussant. Mouse Model of NF2-related meningioma. Scientific Session I. American Association of Neurological Surgeons Annual meeting, San Diego, CA, April 26-May 1, 2003.

93. Jensen RL and Gillepsie D. Hypoxia inducible factor-1 controls growth and angiogenesis in glioblastoma multiforme. American Association of Neurological Surgeons Annual meeting, San Diego, CA, April 26-May 1, 2003.

94. Jensen RL, Shrieve D, Fults D, and Watson G: Gliasite Radiation Therapy System for Treatment of Recurrent Malignant Gliomas and Metastatic Brain Tumors. University of Utah Experience. Submitted for presentation at Rocky Mountain Neurosurgery Society Annual meeting, Big Sky, MT, June 26-May 1, 2003.

95. Jensen RL: Hypoxia Inducible Factor-1 in the growth and angiogenesis of human brain tumors. University of Utah Neuroscience Student Retreat. Midway, Utah, August 22, 2003.

96. Kan P, Gottfied O, and Jensen RL: Oligodendroglioma and juvenile pilocytic astrocytoma presenting as synchronous primary brain tumors. Congress of Neurological Surgeons. Denver, Colorado. September 29-October 4, 2003.

97. Jensen RL and Gillespie D: Vascular endothelial growth factor is inhibited by small interfering ribonucleic acid sequences directed toward the hypoxia inducible factor 1 gene. Congress of Neurological Surgeons. Denver, Colorado. September 29-October 4, 2003.

98. Rao G, Watson G, Shrieve D, Samlowski W, and Jensen RL: Institutional Experience with LINAC based stereotactic radiosurgery for patients with “radioresistant” cerebral metastases. Congress of Neurological Surgeons. Denver, Colorado. September 29-October 4, 2003.

99. Gottfied O, Liu JK, and Jensen RL: Primary Intramedullary Yolk Sac Tumor. Congress of Neurological Surgeons. Denver, Colorado. September 29-October 4, 2003.

100. House P and Jensen RL: Endolymphatic Sac Tumors as part of the von Hippel-Lindau syndrome: Molecular biology and relation to Hypoxia Inducible Factor-1 regulation. Congress of Neurological Surgeons. Denver, Colorado. September 29-October 4, 2003.

101. Jensen RL: State of the Art Management of Brain Metastastes. Invited luncheon panelist. Congress of Neurological Surgeons. Denver, Colorado. September 29-October 4, 2003.

102. Liu JK, O'Neill B, Orlandi RR, Moscatello AL, Jensen RL, and Couldwell WT: Endoscopic-assisted craniofacial resection of esthesioneuroblastoma: Minimizing facial incisions. Technical note and report of 3 cases. Denver, Colorado. September 29-October 4, 2003.

103. Jensen RL: Multimodality Treatment of Malignant Gliomas. Invited luncheon panelist. Congress of Neurological Surgeons. Denver, Colorado. September 29-October 4, 2003.

104. Jensen RL, and Gillespie D: Small Interfering Ribonucleic Acid Sequences Directed Toward the Hypoxia Inducible Factor 1 Gene Inhibits Vascular Endothelial Growth Factor Secretion in Malignant Glioma Cell lines. Society for Neuro-Oncology, Eight Annual Meeting, Keystone Colorado, November 13-16, 2003.

105. Jensen RL: Stereotactic Radiosurgery. University of Utah Mechanical Engineering Graduate Seminar, November 21, 2003.

106. Jensen RL and Gillespie D: The Use of Small Inhibitory Ribosnucleic Acid (siRNA) to inhibit Hypoxia-Inducible Factor-1 (HIF-1) Expression as A Treatment for Malignant Gliomas. Richard Lende Winter Neurosurgical Meeting. Snowbird Utah, February 1-6, 2004.

107. Gillespie D, and Jensen RL: Running interference: Using short RNAs for targeted gene silencing in mammals. Richard Lende Winter Neurosurgical Meeting. Snowbird Utah, February 1-6, 2004.

108. Finn M, Blumenthal D, and Jensen RL: Transient post-ictal MRI changes in patients with brain tumors may mimic disease progression. Richard Lende Winter Neurosurgical Meeting. Snowbird Utah, February 1-6, 2004.

109. Liu J, Ragel BT, Whang K, Gillespie DL, Prescott SM, Couldwell WT, and Jensen RL: R-Flurbiprofen inhibits cell proliferation and induces apoptosis in pituitary adenoma cells in vitro. Richard Lende Winter Neurosurgical Meeting. Snowbird Utah, February 1-6, 2004.

110. Ragel B, Liu JK, Whang K, Gillespie DL, Couldwell WT, and Jensen RL: Cyclooxygenase-2 (COX-2) in meningiomas: A potential therapeutic target. Richard Lende Winter Neurosurgical Meeting. Snowbird Utah, February 1-6, 2004.

111. Jensen RL, Kushnir V, Ragel B, and Gillespie D: Calcium Channel Antagonists Increase the Efficacy of Chemotherapeutic Agents Commonly Used for Treatment of Refractory Meningiomas. North American Skull Base Society. New Orleans, LA, February 14-17, 2004.

112. Ragel B, Couldwell W, and Jensen RL: Cycloxygenase 2 (COX-2) is Expressed in Human Meningiomas and Does Not Correlate with HIF-1 alpha or VEGF Expression. North American Skull Base Society. New Orleans, LA, February 14-17, 2004.

113. Jensen RL: Breakfast with the Professor. North American Skull Base Society. New Orleans, LA, February 14-17, 2004.

114. Jensen RL, and Gillespie D: Small Interfering Ribonucleic Acid Sequences Directed Toward the Hypoxia Inducible Factor 1 Gene Inhibits Vascular Endothelial Growth Factor Secretion in Malignant Glioma Cell lines. American Association of Neurological Surgeons Annual meeting, Orlando, Florida, May 1-6, 2004.

115. Ragel B, Couldwell W, and Jensen RL: Cycloxygenase 2 (COX-2) is Expressed in Human Meningiomas and Does Not Correlate with HIF-1 alpha or VEGF Expression. American Association of Neurological Surgeons Annual meeting, Orlando, Florida, May 1-6, 2004.

116. Jensen RL: Pitfalls in cerebral cortical mapping. Invited participant. Breakfast seminar. American Association of Neurological Surgeons Annual meeting, Orlando, Florida, May 1-6, 2004.

117. Ragel B; Liu JK; Gillespie DL; Whang K; Jensen RL; Couldwell WT: NSAIDs as a Possible Treatment for Meningiomas. Presented at the 39th annual meeting of the Rocky Mountain Neurosurgery Society, Squaw Valley, CA, June 12-16, 2004.

118. Browd SR; Tucker J; Jensen RL; Lee J: fMRI for Neurosurgical Mapping: Integration and Correlation with Intraoperative Mapping Techniques. Presented at the 39th annual meeting of the Rocky Mountain Neurosurgery Society, Squaw Valley, CA, June 12-16, 2004.

119. Jensen RL, Kushnir V, Ragel BT, and Gillespie D: Growth inhibition of chemotherapy for meningiomas is potentiated by calcium channel antagonists. Presented at the 39th annual meeting of the Rocky Mountain Neurosurgery Society, Squaw Valley, CA, June 12-16, 2004.

120. Jensen RL and Gillespie D: Hypoxia inducible factor-1 inhibition by short interfering RNA techniques for the treatment of malignant gliomas. Presented at the 39th annual meeting of the Rocky Mountain Neurosurgery Society, Squaw Valley, CA, June 12-16, 2004.

121. Jensen RL: Implant considerations unique to Gliasite. Invited Panelist at 2004 Gliasite Physician Conference, Chicago, Illinois.

122. Jensen RL: Novel treatments for glioblastoma multiforme. American Association of National Cancer Registries. October 1, 2004. Salt Lake City, Utah.

123. Jensen RL; Kushnir V; Ragel B; Gillespie D: Growth Inhibition Of Meningiomas By Combined Chemotherapeutic And Calcium Channel Antagonists. In Vitro And In Vivo Studies. Presented at the Congress of Neurological Surgeons, San Francisco. October 16th-21st, 2004.

124. Ragel B, Liu JK, Whang K, Gillespie DL and Jensen RL; NSAIDS as a possible treatment for meningiomas. Presented at the Congress of Neurological Surgeons, San Francisco. October 16-21st, 2004.

125. Gillespie DL and Jensen RL: Running interference: Using short RNAs for targeted gene silencing in mammals. Presented at the Congress of Neurological Surgeons, San Francisco. October 16-21st, 2004.

126. Liu JK, Ragel BT, Whang K, Gillespie DL, Jensen RL, Prescott SM, and Couldwell WT: R-Flurbiprofen downregulates cycloxygenase-2 (COX-2) and induces apoptosis in pituitary adenoma cells in vitro. Presented at the Congress of Neurological Surgeons, San Francisco. October 16-21st, 2004.

127. Jensen RL, Gillespie D: Hypoxia inducible factor 1a is upregulated and is the principle mediator of VEGF secretion in malignant gliomas. Presented at the AANS/CNS Section on Tumors Sixth Biennial Satellite Symposium, San Francisco, October 21-22, 2004.

128. Jensen RL. Combined chemotherapeutic and calcium channel antagonists for growth inhibition of meningioms, in vitro and invivo studies. Society for NeuroOncology Ninth Annual Meeting, Toronto, Canada, November 18-21, 2004.

129. Hitchcock Y, Bentz B, Jensen RL, and Sharma P: Second high-grade sarcoma of the mandible within prophylatic cranial irradiation field in a long term survivor of childhood acute lymphocytic leukemia. International Connective Tissue Oncology Society, 2004.

130. Hazard L, Jensen RL, Chern SS, Leavitt DD, and Shrieve DC: Conformity and normal tissue sparing of intensity modulated stereotactic radiotherapy compared to dynamic conformal arc stereotactic radiotherapy. ASTRO 2004.

131. Jensen RL: New Clinical Trials for Malignant Gliomas. Utah State Neurological Society Meeting, Salt Lake City, Utah, December 8, 2005.

132. Jensen RL, Ragel B, Whang K,and Gillespie D: Calcium Channel Antagonists Increases the Efficacy of Chemotherapeutic Agents for Growth Inhibition of Benign and Malignant Meningiomas. In Vitro And In Vivo Studies. Richard Lende Winter Neurosurgical Meeting. Snowbird Utah, January 29- February 2, 2005.

133. Jensen RL, Gillespie D: Hypoxia inducible factor 1a is the major regulator of vascular endothelial growth factor secretion in human gliomas. Accepted for presentation at the AANS Annual Meeting, New Orleans, April 16- 21, 2005.

134. Jensen RL. The Spectrum of Adjuvant Therapy for Brain Tumors. Breakfast Seminar. Accepted for presention at the AANS Annual Meeting, New Orleans, April 16- 21, 2005.

135. Ragel B, and Jensen RL: Hypoxia-induced genes in a malignant glioma cell in (U-251) by cDNA microarray analysis. Accepted for presention at the AANS Annual Meeting, New Orleans, April 16- 21, 2005.

136. Ragel B, and Jensen RL: Celecoxib decreases the growth of malignant meningioma cell line (IOMM-Lee) in the mouse xenograft flank model. Accepted for presention at the AANS Annual Meeting, New Orleans, April 16- 21, 2005.

137. Jensen RL and Gillepie DL: Inhibition of HIF-1± by short hairpin RNA technology inhibits both in vitro and in vivo human glioma cell growth. Accepted for presention at the World Federation of Neuro Oncology, Edinburgh, Scotland, May 3-7, 2005.

138. Jensen RL: The use of animal models to study human brain tumors. Presented at the District 8 AALAS meeting. Park City, Utah, May 23, 2005.

139. Jensen RL and Gillespie DL: In vitro and in vivo glioblastoma multiforme cell growth is inhibited by anti-HIF-1± short hairpin RNA. Preliminary results and drug delivery studies. 40th Annual Meeting of the Rocky Mountain Neurosurgery Society, Whistler, British Columbia, June 18-22, 2005.

140. Samlowski W, Rao G, Klimo P, Thompson C, Wang M, Watson G, Shrieve D, and Jensen RL. Stereotactic radiosurgery (SRS) as therapy for melanoma brain metastases: Impact of added surgical resection and whole brain radiotherapy. 6th World Congress on Melanoma. September 6-10, 2005, Vancouver, CA.

141. Jensen RL and Gillespie DL: Glioblastoma cell growth is inhibited by anti-HIF1a- short hairpin RNA. Animal studies and drug delivery techniques. Accepted for presentation at Congress of Neurological Surgeons Annual Meeting October 9-13, 2005.

142. Jensen RL: Breakfast Seminar: Biology of meningiomas. Accepted for presentation at Congress of Neurological Surgeons Annual Meeting October 9-13, 2005. r construction.